DATASHEET
Host:
Rabbit
Target Protein:
HAS2
Clonality:
Polyclonal
Isotype:
IgG
Source:
KLH conjugated synthetic peptide derived from human HAS2/Hyaluronan synthase 2
Purification:
Purified by Protein A.
Storage Buffer:
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage:
Store at -20°C for 12 months.
Background:
HAS1, HAS2 and HAS3 are HA Synthase proteins that synthesize HA (Hyaluronan or hyaluronic acid). The extracellular matrix in most vertebrates express HA, which is a high molecular weight linear polysaccharide composed of alternating glucuronic acid and N-acetylglucosamine residues linked by β-1,3 and β-1,4 glycosidic bonds. The three HAS genes show distinct patterns of expression during development and their protein products play significantly different roles in the formation of the HA matrix. Both HAS1 and HAS2 synthesise high molecular-weight HA, whereas HAS3 produces lower molecular weight HA. The expression of the three HAS isoforms is more prominent in growing cells than in resting cells and is differentially regulated by various stimuli suggesting distinct functional roles of the three proteins. HAS2 mRNA shows predominant expression in chondrocytes and cartilage. The human HAS2 gene maps to chromosome 8q24.12.
PRODUCT SPECIFIC PUBLICATIONS
- Xinyang Zhao. et al. A Novel Three-Dimensional Follicle Culture System Decreases Oxidative Stress and Promotes the Prolonged Culture of Human Granulosa Cells. ACS APPL MATER INTER. 2023;XXXX(XXX):XXX-XXXRead more>>
- Romana ?nov. et al. The hyaluronan metabolism in the UV-irradiated human epidermis and the relevance of in vitro epidermal models. EXP DERMATOL. 2023 JulRead more>>
VALIDATION IMAGES
Lane 1:Huh7 cell lysates probed with Rabbit Anti-HAS2 Polyclonal Antibody, Unconjugated (bs-11290R) at 1:300 overnight at 4˚C. Followed by conjugation to secondary antibody (bs-0295G-HRP) at 1:5000 for 90 min at RT.
Lane 1: Human U251 cell Lysates; Lane 2: Human U-87 MG cell Lysates; Lane 3: Human Hela cell Lysates. Probed with HAS2 polyclonal Antibody, unconjugated (bs-11290R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.